TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

Similar documents
Your single-source laboratory solution. FISH Probe Library

HEMATOPATHOLOGY SERVICES

DIRECTORY OF SERVICES

September 04, 2008

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

Out-Patient Billing CPT Codes

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

August 17, Dear Valued Client:

Oncology Cytogenetics Diagnostic Service - User Guide 2014

West Midlands Regional Genetics Laboratory

NeoTYPE Cancer Profiles

molecular oncology services

Introducing Western Diagnostic s Genomic Pathology

The Center for PERSONALIZED DIAGNOSTICS

Clinical Cytogenetic Services

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

NeoTYPE Cancer Profiles

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Clinical Cytogenomics Laboratory. Laboratory. Leading diagnostics for better medicine. Beaumont

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Lab Guide 2018 Diagnostic Genomic Division(DGD)

Molecular Diagnosis. Nucleic acid based testing in Oncology

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Outline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature

Please Silence Your Cell Phones. Thank You

Session 7 Summary. Magdalena Czader, MD, PhD David Czuchlewski, MD MOLECULAR GENETICS OF HEMATOPOIETIC NEOPLASMS

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Pediatric Oncology & Pathology Services

Recommended Timing for Transplant Consultation

scfish: A Primer Peter K. Rogan, Ph.D. Joan H. M. Knoll, Ph.D., FACMG, FCCMG Children s Mercy Hospitals and Clinics Tuesday, July 29, 2003

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Introduction to Cytogenetics

Hematology Diagnostic Services

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run

Objectives and Financial Disclosure

MOLECULAR SERVICES. mlabs.umich.edu

The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare

Molecular Genetic Testing for the Diagnosis of Haematological Malignancies

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Laboratory Service Report

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

ADRL Advanced Diagnostics Research Laboratory

Session 4: Summary and Conclusions

Cardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample:

Treatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

CLL Complete SM Report

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Chapter 2 Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Increasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

Genetic Testing Oncology

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

Laboratory Service Report

ACMG/CAP Cytogenetics CY

Prior Authorization Required: Additional Information:

Application of Whole Genome Microarrays in Cancer: You should be doing this test!!

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Coverage Determinations Colorectal Carcinoma

CYTOGENETICS Dr. Mary Ann Perle

CGC myeloid malignancy working group updates. Xinjie Xu & Rashmi Kanagal-Shamanna

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Diagnostic Molecular Pathology of Myeloid Neoplasms

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

MOC MGP General Molecular Genetics I (Mandatory 75-Question Module) analytical measurement range; CLSI MM06-A2 PCR assay performance and validation

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma

Acute leukemia and myelodysplastic syndromes

Molecular Hematopathology

Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose

Myelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.

We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university

Supporting Information

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

Current Techniques in Molecular Biology Friedel Nollet, Ph.D.

The Evolving Role of Transplantation for MPN

Transcription:

TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Leukemic Blood 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Lymph Node 88233 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Mass/Solid Tumor 88233 x 2, 88264, 88280 x 3, 88291 14 Days Chromosome Analysis Peritoneal Fluid 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Pleural Fluid 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Fixed Pellet 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Fine Needle Aspirate 88237 x 1, 88264, 88280 x 3, 88291 4 Days FLUORESCENCE IN SITU HYBRIDIZATION (FISH) FISH - Single (Whole Specimen or Pellet) 88271 (per probe), 88275 (per probe), 88291 4 Days FISH Single (Paraffin Embedded Tissue Slides) 88271 (per probe), 88275 (per probe), 88291 7 Days FISH Multi - (Whole Specimen or Pellet) 88271 x 2 (per probe), 88275 (per probe), 88291 4 Days FISH Multi - (Paraffin Embedded Tissue Slides) 88271 (per probe), 88275 (per probe), 88291 7 Days FISHnet / ifish (enrichment only) 88112 (FISH codes will also apply see above) 4 Days (See below for list of FISH probes by profile and in numerical order.) (FISH may be performed on the following specimen types: Bone Marrow, Bone Marrow Core, Leukemic Blood, Lymph Node, Mass/Solid Tumor, Paraffin Embedded Tissue Slides, Pleural Fluid, and Peritoneal Fluid.)

FISH PROBES BY PROFILE Adult B-Cell ALL profile del(9p) CDKN2A del(6q) CCND3/SEC63/MYB t(9;22) BCR/ABL1/ASS1 11q23 KMT2A (MLL) rearrangements t(1;19) TCF3/PBX1 14q32 IGH rearrangements Adult T-Cell ALL profile 14q11.2 TRA rearrangements 7q34 TRB rearrangements 10q24 TKX1 5q35 TLX3 11q23 KMT2A (MLL) rearrangements del(9p) CDKN2A Pediatric ALL profile (COG) t(12;21) ETV6/RUNX1 11q23 KMT2A (MLL) rearrangements t(9;22) BCR/ABL1/ASS1 trisomy 4,10,17 14q32 IGH rearrangement Additional probes t(1;19) TCF3/PBX1 Ph-Like ALL profile 1q25.2 ABL2 5q32 PDGFRb 5q32 CSF1R 9p24.1 JAK2 9q34.1 ABL1 19p13.2 EPOR Xp22.33/Yp11.3 CRFL2 Acute Myelogenous (AML) profile t(15;17) PML/RARA t(9;22) BCR/ABL1/ASS1 CLL Lymphocytic (CLL) profile (CD19+ Clones Available) del(11q) ATM t(8;21) RUNX1T1/RUNX1 trisomy 12 11q23 KMT2A (MLL) rearrangements inv(16), t(16;16) CBFB rearrangements inv(3) MECOM rearrangements 17q RARA rearrangements NUP98 11p15 del(13q) 13q14/13q34 del(17p) TP53 Additional Probes t(11;14) CCND1/IGH del(6q) CCND3/SEC63/MYB

Chronic Myelogenous (CML) profile t(9;22) BCR/ABL1/ASS1 Additional probes trisomy 8 i(17q) Lymphoma probes (CD19+ Clones Available) t(8;14) MYC/IGH (Burkitt or Follicular) 8q24 MYC rearrangements t(11;14) CCND1/IGH (Mantle Cell) t(11;18) BIRC3/MALT1 18q21 BCL2 rearrangements 18q21 MALT1 rearrangements t(14;18) IGH/BCL2 (Follicular or Diffuse Large B-Cell) 3q27 BCL6 rearrangements (Diffuse Large B-Cell, Follicular Marginal Zone B-cell) T-cell Leukemia/Lymphoma probes 2p23 ALK (Anaplastic) rearrangements Multiple Myeloma CD138 Enriched (MM) profile (FISHnet ) 1p32.3/1q21 CDKN2C/CKS1B 14q11.2 TRA rearrangements del(13q) 13q14/13q34 7q34 TRB rearrangements i(7q) 7cen/7q22/7q31 14q32 TCL1A 10q24 TLX1 5q35 TLX3 del(17p) TP53 t(11;14) CCND1/IGH t(4;14) FGFR3/IGH t(14;16) IGH/MAF Additional probes trisomy 5 8q24 MYC rearrangements t(6;14) CCND3/IGH t(14;20) IGH/MAFB

Myelodysplastic (MDS) profile del(5q) EGR1 Myeloproliferative (MPN) profile del(5q) EGR1 del(7q) / monosomy 7 del(7q) / monosomy 7 trisomy 8 trisomy 8 del(20q) Additional probes 11q23 KMT2A (MLL) rearrangements t(9;22) BCR/ABL1/ASS1 NUP98 11p15 del(20q) t(9;22) BCR/ABL1/ASS1 Additional probes 4q12 FIP1L1/CHIC2/PDGFRA 5q33 PDGFRB rearrangements 8p11 FGFR1 rearrangements 9q24 JAK2 rearrangements Solid Tumor probes EWSR1 Ewing Sarcoma Transplant XX/XY for sex mismatched transplants FOXO1 Alveolar Rhabdomyosarcoma DDIT3 (CHOP) Myxoid Liposarcoma LOH 1p/19q Glioma MYCN 2p24.1 Neuroblastoma SS18 Synovial Sarcoma Bladder Cancer Screening (Trisomy 3, 7, 17, & 9p21 loss)

FISH PROBES NUMERICALLY Chromosome # Probe Location on Cancer Requisition 1 1p32.3/1q21 CDKN2C/CKS1B Multiple Myeloma Profile 1 1q25.2 ABL2 Ph Like ALL profile 1, 19 t(1;19) TCF3/PBX1 Adult B-Cell ALL profile Pediatric ALL profile 1, 19 1p/19q LOH (Glioma) Solid Tumor probes 2 2p23 ALK (Anaplastic) rearrangements T-cell Leukemia/Lymphoma probes 2 2p24.1 MYCN (Neuroblastoma) Solid Tumor probes 3 inv(3) MECOM rearrangements Acute Myelogenous (AML) profile 3 3q27 BCL6 rearrangements (Diffuse Large B-Cell, Follicular, Marginal Zone B-cell) Lymphoma probes 4, 10, 17 trisomy 4,10,17 Pediatric ALL profile 4 4q12 FIP1L1/CHIC2/PDGFRA Myeloproliferative (MPN) profile 4, 14 t(4;14) FGFR3/IGH Multiple Myeloma Profile 5 del(5q) EGR1 / trisomy 5 Multiple Myeloma Profile Myeloproliferative (MPN) profile Myelodysplastic (MDS) profile 5 5q33 PDGFRB rearrangements Multiple Myeloma Profile Ph Like ALL Profile 5 5q32 CSF1R Ph Like ALL Profile 5 5q35 TLX3 Adult T-Cell ALL profile

Chromosome # Probe Location on Cancer Requisition 6 del(6q) CCND3/SEC63/MYB Adult B-Cell ALL profile Chronic Lymphocytic (CLL) profile 6, 14 t(6;14) CCND3/IGH Multiple Myeloma Profile 7 del(7q) / monosomy 7 / trisomy 7 Multiple Myeloma Profile Myelodysplastic (MDS) profile Myeloproliferative (MPN) profile 7 i(7q) 7cen/7q22/7q31 T-cell Leukemia/Lymphoma probes 7 7q34 TRB rearrangements Adult T-Cell ALL profile T-cell Leukemia/Lymphoma probes 8 trisomy 8 (CHARGE) Chronic Myelogenous (CML) profile Myelodysplastic (MDS) profile Myeloproliferative (MPN) profile 8 8p11 FGFR1 rearrangements Myeloproliferative (MPN) profile 8 8q24 MYC rearrangements Lymphoma probes 8,14 t(8;14) MYC/IGH (Burkitt or Follicular) Lymphoma probes 8, 21 t(8;21) RUNX1T1/RUNX1 Acute Myelogenous (AML) profile 9 9q24 JAK2 rearrangements Myeloproliferative (MPN) profile 9 del(9p) CDKN2A Adult B-Cell ALL profile Adult T-Cell ALL profile 9 9q34.1 ABL1 Ph Like ALL Profile

Chromosome # Probe Location on Cancer Requisition 9, 22 t(9;22) BCR/ABL1/ASS1 Adult B-Cell ALL profile Pediatric ALL profile Acute Myelogenous (AML) profile Chronic Myelogenous (CML) profile Myelodysplastic (MDS) profile Myeloproliferative (MPN) profile 10 10q24 TLX1 Adult T-Cell ALL profile T-cell Leukemia/Lymphoma probes 11 NUP98 11p15 Acute Myelogenous (AML) profile Myelodysplastic (MDS) profile 11 del(11q) ATM Chronic Lymphocytic (CLL) profile 11 11q23 KMT2A (MLL) rearrangements Myelodysplastic (MDS) profile Adult B-Cell ALL profile Adult T-Cell ALL profile Pediatric ALL profile Acute Myelogenous (AML) profile 11, 14 t(11;14) CCND1/IGH Chronic Lymphocytic (CLL) profile t(11;14) CCND1/IGH (Mantle Cell) t(11;14) CCND1/IGH Lymphoma probes Multiple Myeloma Profile 11, 18 t(11;18) BIRC3/MALT1 Lymphoma probes 12 trisomy 12 Chronic Lymphocytic (CLL) profile 12 12q13 DDIT3 (CHOP) Myxoid Liposarcoma Solid Tumor probes 12, 21 t(12;21) ETV6/RUNX1 Pediatric ALL profile

Chromosome # Probe Location on Cancer Requisition 13 del(13q) 13q14/13q34 Chronic Lymphocytic (CLL) profile Multiple Myeloma Profile 13 13q14.1 FOXO1 Alveolar Rhabdomyosarcoma Solid Tumor probes 14 14q11.2 TRA rearrangements Adult T-Cell ALL profile T-cell Leukemia/Lymphoma probes 14 14q32 IGH rearrangements Adult B-Cell ALL profile Pediatric ALL profile 14 14q32 TCL1A T-cell Leukemia/Lymphoma probes 14, 16 t(14;16) IGH/MAF Multiple Myeloma Profile 14, 18 t(14;18) IGH/BCL2 (Follicular or Diffuse Large B-Cell) Lymphoma probes 14, 20 t(14;20) IGH/MAFB Multiple Myeloma Profile 15, 17 t(15;17) PML/RARA Acute Myelogenous (AML) profile 16 inv(16), t(16;16) CBFB rearrangements Acute Myelogenous (AML) profile 17 del(17p) TP53 Chronic Lymphocytic (CLL) profile del(17p) TP53 Multiple Myeloma Profile 17 i(17q) Chronic Myelogenous (CML) profile 17 17q RARA rearrangements Acute Myelogenous (AML) profile 18 18q11.2 SS18 Synovial Sarcoma Solid Tumor probes 18 18q21 BCL2 rearrangements Lymphoma probes 18 18q21 MALT1 rearrangements Lymphoma probes 19 19p13.2 EPOR Ph Like Profile 20 del(20q) Myelodysplastic (MDS) profile Myeloproliferative (MPN) profile

Chromosome # Probe Location on Cancer Requisition 22 22q12.2 EWSR1 Ewing Sarcoma Solid Tumor probes 3, 7, 9, 17 Bladder Cancer Screening Solid Tumor probes X/Y CEPXY (XX/XY for sex mismatched transplant) Transplant X/Y Xp22.33/Yp11.3 CRFL2 Ph Like ALL Profile CHROMOSOME MICROARRAY Microarray (SNP) 81229 10 Days NEXT GENERATION SEQUENCING (NGS) NGS 81450 14 Days (See below for list of NGS panels.) Panel AML Molecular Profile MDS Molecular Profile MPN Molecular Profile MPN Targeted Molecular Profile Myeloid Complete Molecular Profile Included Genes ASXL1, CBL, CEBPA, CSF3R, DNMT3A, EZH2, IDH1, IDH2, JAK2, KIT, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 ASXL1, EZH2, DNMT3A, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1 ABL1, CALR, CSF3R, EZH2, JAK2, MPL, SETBP1 JAK2, MPL, CALR ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, EZH2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1

POLYMERASE CHAIN REACTION (PCR) BCR/ABL p210 BKPT 81206 4 Days BCR/ABL p190 BKPT 81207 4 Days FLT3 Mutation Detection 81245, 81246 4 Days IgVH Hypermutation Analysis 81263 4 Days JAK2 81270 4 Days T-Cell Clonality Assessment 81340, 81342 4 Days B-Cell Clonality Assessment 81264, 81261 4 Days

CONSTITUTIONAL / PRENATAL CHROMOSOME ANALYSIS Chromosome Analysis Amniotic Fluid 88235 X 2, 88267, 88261, 88280, 88291 7 Days Chromosome Analysis CVS 88235 X 2, 88267, 88261, 88280, 88172, 88291 7 Days Chromosome Analysis Newborn Peripheral Blood 88230 x 2, 88262, 88280, 88291 5 Days Prelim 48 hours Chromosome Analysis Peripheral Blood 88230 x 2, 88262, 88280, 88291 5 Days Chromosome Analysis POC 88305, 88233x2, 88261, 88267, 88280 10 Days Chromosome Analysis Tissue 88233 x 2, 88264, 88280 x 3, 88291 14 Days CHROMOSOME MICROARRAY Microarray (SNP) 81229 10 Days FLUORESCENCE IN SITU HYBRIDIZATION (FISH) FISH (Microdeletion) 88271, 88273, 88291 5 Days AneuVysion FISH Amniotic Fluid 88271 x 5, 88275, 88291 24 hours AneuVysion FISH Paraffin Embedded Slides 88271 x 5, 88275, 88291 7 Days POC FISH Product of Conception Tissue 88271 x 8, 88275 X 2, 88291 3 Days POC FISH Paraffin Embedded Slides 88271 x 8, 88275 X 2, 88291 7 Days (See below for list of FISH probes by profile and in numerical order.) (FISH may be performed on the following specimen types: Bone Marrow, Bone Marrow Core, Leukemic Blood, Lymph Node, Mass/Solid Tumor, Paraffin Embedded Tissue Slides, Pleural Fluid, and Peritoneal Fluid.)

CONSTITUTIONAL / PRENATAL FISH PROBES BY PROFILE Microdeletion Syndromes Angelman (15q12) Cri-du-Chat (5p15.3) DiGeorge (22q11.2) Other Trisomy 13 Patau Syndrome Trisomy 18 Edwards Syndrome Trisomy 21 Down Syndrome DiGeorge II (10p14) Kallman (Xp22.3) Panels 1p36 microdeletion AneuVysion (X, Y, 13, 18, 21) Miller-Dieker (17p13.3) POC FISH (X, Y, 13, 15, 16, 18, 21, 22) Pallister-Killian/Tetrasomy 12p Phelan-McDermid (22q13) Prader-Willi (15q12) Saethre-Chotzen (7p21.1) Sex Chromosome Abnormalities X/SRY (Sex Determination) CEPX/CEPY (Turner Syndrome) Smith-Magenis (17p11.2) Sotos (5q35.3) Steroid Sulfatase Deficiency (Xp22.3) Williams (7q11.23) Wolf-Hirschhorn (4p16.3)

CONSTITUTIONAL / PRENATAL FISH PROBES NUMERICALLY by CHROMOSOME Chromosome # Probe 1 1p36 microdeletion 4 Wolf-Hirschhorn (4p16.3) 5 Cri-du-Chat (5p15.3) 5 Sotos (5q35.3) 7 Saethre-Chotzen (7p21.1) 7 Williams (7q11.23) 10 DiGeorge II (10p14) 12 Pallister-Killian/Tetrasomy 12p 13 Trisomy 13 Patau Syndrome 15 Angelman (15q12) 15 Prader-Willi (15q12) 17 Miller-Dieker (17p13.3) 18 Trisomy 18 Edwards Syndrome 21 Trisomy 21 Down Syndrome 22 DiGeorge (22q11.2) 22 Phelan-McDermid (22q13) X Kallman (Xp22.3) X Steroid Sulfatase Deficiency (Xp22.3) X/SRY X/SRY - Sex Determination CEPX/CEPY CEPX/CEPY - Turner Syndrome Panels X,Y,13,18,21 AneuVysion X,Y,13,15,16,18,21,22 POC FISH

CONSTITUTIONAL / PRENATAL POLYMERASE CHAIN REACTION (PCR) Thrombophilia Panel (Factor II, Factor V, MTHFR) 81240, 81241, 81291 4 Days ADDITIONAL SENDOUT TESTING Cystic Fibrosis 81221 7 Days Fragile X 81243, 81244 10 Days AZF-Y Microdeletion 81479 10-12 Days